Pharmacy Technician 2 - Infusion

BIDMC and Dana-Farber bring new care model and treatment advances to breast cancer patients as part of collaboration. October 16, 2026 BOSTON - Beth Israel Deaconess Medical Center (BIDMC) and Dana-Farber Cancer Institute announced that on October 19, clinical services for breast oncology will fully transition to a new model that delivers outstanding multidisciplinary care as part of a clinical collaboration between the two hospitals. Outpatient breast oncology services will be provided at Dana-Farber, home to the largest clinical breast cancer program in New England, while breast cancer surgical services will be provided by a renowned team of surgeons at BIDMC from Harvard Medical Faculty Physicians at BIDMC (HMFP). Breast oncology is the first treatment center to transition as part of a phased approach that will happen over the next several years. The surgical team is led by Elizabeth Mittendorf, MD, PhD, MHCM, Chief of the Division of Breast Surgery at BIDMC; chief of Multi-Disciplinary Oncology at Dana-Farber; and co-leader of the Breast Program for the Harvard Cancer Consortium. Mittendorf also serves as President of the American Society of Clinical Oncology (ASCO), a role in which she helps shape and inform oncology care across the country. She is internationally recognized as a groundbreaking innovator in immunotherapy for breast cancer. Previously, Mittendorf was the Rob and Karen Hale Endowed Chair of Surgical Oncology at Brigham and Women's Hospital. "I've had the privilege of working side-by-side with this team of breast surgeons and can confidently say they are among the best in the world - passionate about delivering the best possible care for our patients while also collaborating with our multi-disciplinary colleagues to drive clinical excellence and future innovations in breast cancer care," said Mittendorf. "Our new care model allows us to deliver extraordinary, highly personalized care to patients while pushing the boundaries of innovation in cancer research." More personalized care with AI mammography. BIDMC was the first hospital in the country to offer Clairity Breast, the first FDA-authorized artificial intelligence software that analyzes a woman's routine mammogram to help determine whether they are at risk of developing breast cancer in the future. Clairity Breast supplements the standard screening mammogram to generate an individual's five-year risk of developing breast cancer. "Incorporating Clairity is part of our broader breast cancer screening effort to make risk assessments more accessible," said Mittendorf. "We are the first hospital in the country to offer this service, which will hopefully allow us to find breast cancers in the earliest and most treatable stages, and deliver more personalized screenings for women." To date, 125 women have utilized the Clairity screening tool at BIDMC with 550 additional screening appointments scheduled in the coming months. Largest portfolio of Breast cancer clinical trials continues to grow. Dana-Farber is home to the largest portfolio of breast cancer clinical trials in New England. These scientific studies are designed to evaluate new and promising treatments - including drugs, diagnostic procedures, and other therapies - in patients to help determine their safety and effectiveness. Nearly all cancer drugs in use today have undergone testing in clinical trials. "Clinical trials are the bedrock of cancer research, helping to advance new medicines and further improve care practices," said Sara Tolaney, MD, MPH, Chief of Breast Oncology at Dana-Farber Cancer Institute. "Importantly, clinical trials also give our patients the opportunity to benefit from new and potentially groundbreaking therapies, in many instances, long before they are approved by the FDA. We are proud to offer a large and growing portfolio of clinical trials for every type of breast cancer so that our patients have access to the best possible medicines and practices." Clinical trials are available at Dana-Farber for every type of breast cancer - from early-stage to metastatic disease, as well as rare subtypes such as male breast cancer and inflammatory breast cancer. Surgical clinical trials are also available at BIDMC to help alleviate lymphedema, improve breast reconstruction, advance less invasive surgical techniques and enhance quality of life. In just the past year, three new breast cancer therapies have been approved by the FDA based on Dana-Farber-led clinical studies which have set a new standard of care for HER2+ metastatic breast cancer, triple-negative metastatic breast cancer and hormone-receptor positive breast cancer. Multidisciplinary, patient-centered care. "Breast cancer is not one disease, but rather a series of very specific subtypes that require different therapies and approaches, each tailored to the individual patient," said Mittendorf. "As surgeons at BIDMC, we are working hand-in-glove with our colleagues in breast oncology at Dana-Farber, and radiation oncology, pathology, reconstructive surgery, and across other disciplines to deliver the best possible care and outcomes for our patients." Beyond expert surgical and clinical care, breast cancer patients at Dana-Farber and BIDMC have access to fertility preservation services to help women undergoing cancer treatment preserve their ability to start a family, psychosocial support, genetic testing to inform future cancer risk and guide treatment decisions, expert geriatric care, and complementary therapies to ease treatment-related symptoms. Dana-Farber has also established leading evidenced-based programs and centers of excellence to support patients with specific breast cancer types such as Young and Strong which offers tailored support for the unique needs of young women with breast cancer, EMBRACE for patients living with metastatic breast cancer, the program for older adults with breast cancer, among many others specialties. Meanwhile, BIDMC is home to the Boston Lymphatic Center which provides leading care for patients effected by lymphedema, a common and difficult breast cancer side effect, as well as Comprehensive Breast Care Center which offers multidisciplinary, comprehensive risk assessment, surveillance and prevention program for women known to be at increased risk and for those interested in learning about their risk for breast cancer. "No two patients are exactly alike, which is why we design our therapies and support programs for each individual we care for," said Tolaney. "We are excited to offer our patients an even broader portfolio of resources and expert care through our collaboration with our colleagues at BIDMC and to further grow our personalized breast cancer care model." About Beth Israel Deaconess Medical Center. Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education. Director, Media Relations Sarah finlaw. Please note: The contact information above is for journalists and news media only. For patient care and all other inquiries, please contact your doctor or hospital directly.

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal. * Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors * Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites * APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade >=3 treatment-related adverse events * Disease stabilization was observed in 5 of 10 RECIST-evaluable patients Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - invIOs GmbH ("invIOs"), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, "Phase I Evaluation of APN401, an Autologous CBL-B-Silenced PBMC Therapy, in Advanced Solid Tumors", reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors. A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade >=3 treatment-related adverse events. The highest dose of 4.5 x 10[7] PBMCs/kg was selected as the recommended Phase 2 dose. Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit. APN401 is an autologous cell therapy utilizing patients' own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells. Romana Gugenberger, PhD, Managing Director of invIOs, commented: "We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors." APN401 is produced using invIOs' proprietary EPiC(R) point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration. About invIOs invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs' proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient's fresh immune cells, enabling rapid treatment in an out-patient setting. The platform's lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types. INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications. For further information, please visit www.invios.com and connect with us on LinkedIn.Vienna, Austria, Oct. 15, 2026 (GLOBE NEWSWIRE) - | invIOs Romana Gugenberger, PhD Managing Director T +43 1 8656577 0 Email: [email protected] | MC Services AG Dr. Cora Kaiser, Dr. Regina Lutz T +49 89 210 228 0 US: Laurie Doyle T +1-339-832-0752 Email: [email protected] | Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Joyce Liu wins prestigious award from the National Cancer Institute. Posted date October 9, 2026 Joyce Liu, MD, MPH of Dana-Farber Cancer Institute is the recipient of the 2026 Michaele C. Christian Oncology Drug Development Award and Lectureship from the National Cancer Institute (NCI). The prestigious honor awarded annually recognizes individuals who have made significant contributions to the development of novel investigational agents for cancer therapy. Liu serves as associate chief and clinical research director of the Division of Gynecologic Oncology at Dana-Farber. In these roles, Liu has successfully developed and led multiple investigator-initiated and industry-sponsored phase 1 and 2 trials in GYN cancers, including early development of antibody-drug conjugates and combinations of PARP inhibitors with immuno-oncology agents. Her work has helped to establish the Dana-Farber GYN research program as a leading center for phase 1 and 2 trial development. Liu also serves as the associate clinical research officer for Dana-Farber. In presenting the award today, the National Cancer Institute stated, "Through her innovative clinical and translational research, Dr. Liu has advanced novel therapeutic strategies for ovarian and endometrial cancers, led practice-changing National Cancer Institute-sponsored clinical trials and championed the development of targeted therapies that have improved treatment options for patients worldwide." Liu's research focuses on identifying and validating novel therapies for gynecologic cancers, with an emphasis on rationally-designed, translationally-driven trials. Early in her career, she identified ErbB3 as a potential therapeutic target in ovarian cancer, leading to an international phase 2 trial of an ErbB3-directed antibody in conjunction with paclitaxel chemotherapy in recurrent platinum-resistant ovarian cancer. Dr. Liu also led the NCI-sponsored trial CTEP 8348 of combination cediranib and olaparib, which was the first trial to demonstrate the activity of combined anti-angiogenic and PARP inhibitor therapy in recurrent ovarian cancer. These results led to the NCI-sponsored international phase 3 NRG-GY004 trial comparing this combination to conventional chemotherapy in recurrent platinum-sensitive ovarian cancer, as well as CTEP 9825, a biomarker-driven phase 2 trial exploring potential biomarkers of sensitivity to this combination. Throughout her career, Liu has been an active member and leader within the NCI clinical trials network. Based upon work showing pre-clinical synergy between MEK inhibition and Bcl-xL inhibition in models of recurrent ovarian cancer, Liu developed and led CTEP 10597, a phase 1 trial testing the combination of cobimetinib with the Bcl-xL inhibitor pelcitoclax in recurrent ovarian and endometrial cancers, and she was an active contributor to CTEP 9525, a phase 1/2 study testing the combination of trametinib and navitoclax across solid tumors. Liu is also the current vice chair for the Ovarian Subcommittee of the NCI-funded NRG Oncology cooperative group. Liu is an active clinical trialist and is a principal investigator on multiple investigator-initiated and externally-sponsored interventional clinical studies in ovarian and endometrial cancer. She led the first trial demonstrating the clinical activity of WEE1 inhibition in uterine serous cancer and is a multi-PI of a P01 grant stemming from this work that is focused on understanding the role of replication stress in high-grade endometrial cancers. She also leads the Dana-Farber Gynecologic Oncology Division's translational modeling efforts and has developed panels of patient-derived xenograft and organoid models of ovarian and endometrial cancers that have provided insights into multiple novel therapeutic targets. Liu joins Panos Konstantinopoulos, MD, PhD (2022) and Geoff Shapiro, MD, PhD (2013) as Dana-Farber recipients of the Michaele C. Christian Oncology Drug Development Award. Gynecologic Cancer Related Doctors and Researchers Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Joyce F. Liu, MD, MPH